Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7775-7782

  Macedo, Luciana F ^a   Guo, Zhiyong ^a   Tilghman, Syreeta L ^a   Sabnis, Gauri J ^a   Qiu, Yun ^a   Brodie, Angela ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; BICALUTAMIDE; ESTRADIOL; ESTROGEN; LETROZOLE; PROTEIN BCL 2; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER GROWTH; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; MITOSIS INHIBITION; PRIORITY JOURNAL;

ANDROGENS; ANDROSTENEDIONE; AROMATASE; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DIHYDROTESTOSTERONE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TRANSFECTION; TRIAZOLES;

EID: 33747886393     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3984     Document Type: Article

References (48)

1. Davidson NE, Lippman ME. The role of estrogens in growth regulation of breast cancer. Crit Rev Oncog 1989;1:89-111.
2. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.
3. Kiss R, De Launoit Y, Wouters W, et al. Inhibitory action of androstenedione on the proliferation and cell cycle kinetics of aromatase-free MXT and MCF-7 mammary tumor cell lines. Eur J Cancer Clin Oncol 1989;25:837-43.
4. Di Monaco M, Leornardi L, Gatto V, Gallo M, Brignardello E, Boccuzzi G. Dihydrotestosterone affects the growth of hormone-unresponsive breast cancer cells: an indirect action. Anticancer Res 1995;15:2581-4.
5. Yeap BB, Krueger RG, Leedman PJ. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 1999;140:3282-91.
6. Andò S, De Amicis F, Rago V, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121-8.
7. Ortmann J, Prifi S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T, Rabe T. Testosterone and 5α-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002;16:113-20.
8. Cip1/WF1. J Mol Endocrinol 2004;32:793-810.
9. Poulin R, Baker D, Labrie F. Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 1988;12:213-25.
10. Kennedy BJ. Fluxymesterone therapy in treatment of advanced breast cancer. N Engl J Med 1958;259:673-5.
11. Cooperative Breast Cancer Group. Testosterone propionate therapy of breast cancer. JAMA 1964;188:1069-72.
12. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM. Calusterone (7β,17α-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology 1973;28:138-46.
13. Ingle JN, Twito DI, Schaid DJ, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone vs. tamoxifen alone in postmenopausal women with metastatic breast cancer. A phase II study. Cancer 1991;67:886-91.
14. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003;98:703-11.
15. Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 1999;140:416-21.
16. Leung LK, Wang TT. Paradoxical regulation of Bcl-2 family proteins by 17β-oestradiol in human breast cancer cells MCF-7. Br J Cancer 1999;81:387-92.
17. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
18. Brodie AM, Njar VC. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications. J Steroid Biochem Mol Biol 1998;66:1-10.
19. Miller WR, O'Neill JS. The significance of steroid metabolism in human cancer. J Steroid Biochem Mol Biol 1990;37:317-25.
20. Reed MJ, Owen AM, Lai LC, et al. In situ oestrone synthesis in normal breast and breast tumor tissues: effect of treatment with 4- hydroxyandrostenedione. Int J Cancer 1989;44:233-7.
21. Szymczak J, Milewicz A, Thijssen JH, Blankenstein MA, Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids 1998;63:319-21.
22. Blankenstein MA, Maitimu-Smeele I, Donker GH, et al. On the significance of in situ production of oestrogens in human breast cancer tissue. J Steroid Biochem Mol Biol 1992;41:891-6.
23. Brodie A, Lu Q, Nakamura J. Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol 1997;61:281-6.
24. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30.
25. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 2005;11:884-8s.
26. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AMH. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44.
27. Jelovac D, Macedo L, Handaratta V, et al. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res 2004;10:7375-81.
28. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
29. Zhou D, Pompom D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54.
30. Jiang T, Guo Z, Dai B, et al. Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage. J Biol Chem 2004;279:50181-9.
31. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003;33:401-6.
32. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
33. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271-7.
34. Long B, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AMH. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998;67:293-304.
35. Filardo EJ, Quinn JA, Frackelton AR, Jr., Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 2002;16:70-84.
36. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways activated by aromatase inhibitors. Cancer Res 2003;63:8037-50.
37. Mistry P, Griffiths K, Maynard PV. Endogenous C19-steroids and estradiol levels in human primary breast tumor tissues and their correlation with androgen and estrogen receptors. J Steroid Biochem 1986;24:1117-25.
38. Jorgensen L, Brunner N, Spang-Thomsen M, et al. Steroid metabolism in the hormone dependent MCF-7 human breast carcinoma cell line and its two hormone resistant subpopulations MCF-7/LCC1 and MCF-7/LCC2. J Steroid Biochem Mol Biol 1997;63:275-81.
39. Maggiolini M, Donzé O, Jeannin E, Andò S, Picard D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer Res 1999;59:4864-9.
40. Panet-Raymond V, Gottlieb B, Beitel LK, Pinsky L, Trifiro MA. Interactions between androgen and estrogen receptors and the effects on their transactivational properties. Mol Cell Endocrinol 2000;167:139-50.
41. Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Andò S. Endogenous coactivator ARA70 interacts with estrogen receptor α (ERα) and modulates the functional ERα/androgen receptor interplay in MCF-7 cells. J Biol Chem 2005;280:20421-30.
42. Kandouz M, Lombet A, Perrot J-Y, et al. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Mol Biol 1999;69:463-71.
43. Reed JC. Double identity for proteins of the Bcl-2 family. Nature 1997;387:773-6.
44. Dong L, Weili W, Wang F, et al. Mechanism of transcriptional activation of bcl-2 gene expression by 17β-estradiol in breast cancer cells. J Biol Chem 1999;274:32099-107.
45. Huang H, Zegarra-Moro L, Benson D, Tindall D. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein cancer cells. Oncogene 2004;23:2161-76.
46. Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A, Secreto G. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. J Steroid Biochem Mol Biol 1995;52:541-6.
47. Suzuki T, Darnel AD, Akahira JI, et al. 5alpha-reductoses in human breast carcinoma: possible modulator of in situ androgenic actions. J Clin Endocrinol Metab 2001;86:2250-7.
48. Wooster R, Mangion J, Eeles R, et al. A germline mutation in the androgen receptor in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2:132-4.